Navigation Links
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Date:11/7/2007

>ACR 50 7.6 38.0* 39.9*

ACR 70 3.5 21.2* 23.2*

Six and 12 month mean mTSS changes from baseline for RAPID 1

CIMZIA(R) CIMZIA(R)

(certolizumab (certolizumab

pegol) pegol)

Placebo & MTX 200mg & MTX 400mg & MTX

Six months 1.3 0.2* 0.2*

12 months 2.8 0.4* 0.2*

*p<0.001

In the six-month RAPID 2 trial, 619 patients were randomly allocated to receive one of three treatment regimens:

-- 246 patients received 400 mg formulation CIMZIA at the start of the

study and at weeks two and four, then 200 mg given every two weeks,

together with methotrexate;

-- 246 patients received 400 mg formulation CIMZIA every two weeks,

together with methotrexate;

-- 127 patients received placebo every two weeks, together with

methotrexate.

In all three arms of the study the dose of methotrexate was 10mg per week or greater. Patients were assessed for improvement in signs and symptoms of RA. The primary endpoint for the study RAPID 2 was ACR20 responder rate at week 24.

In both studies, CIMZIA given at a dosage of 200mg every two weeks was equally effective as a dosage of 400mg every two weeks.

Six month ACR Responses for RAPID 2

CIMZIA(R) CIMZIA(R)

(certolizumab (certolizumab

pegol) pegol)

Placebo & MTX 200mg & MTX 400mg & MTX

ACR 20 8.7 57.3
'/>"/>

SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
(Date:7/24/2014)... July 24, 2014 LSI Medience Corporation ... Agreement with Kineticos, a Raleigh-Durham, NC ... will support LSI Medience in identifying opportunities for ... demonstrate utility in clinical trials. The ... in diagnosis of sepsis, prognosis of septic patients, ...
(Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2
... ONXX ) today announced that it will present at the Canaccord ... a.m. Eastern Time ( 5:00 a.m. Pacific Time ). , ... Interested parties may access a live webcast of the presentation on our website ... It is recommended that ...
... Aug. 3 On June 9, 2010 , Invivo was recognized ... and DynaTRIM (Trans-Rectal Interventional MRI) clinical solutions. The MDEA awards ceremony took place in ... gold and silver winners were honored. , , ... (Photo:   http://photos.prnewswire.com/prnh/20100803/SF44927 ) , , , ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 3
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 DON’T PAUSE ... help alleviate uncomfortable bloating, hot flashes, mood swings, burning ... identified by Dr. Shoreh Ershadi. The AntiAging Institute of California ... Menopause that allows women to try this revolutionary product. For ... PAUSE can get a third bottle at no charge. ...
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... Researchers at the University of Bordeaux in Bordeaux, France have ... man-made material used in high-heat insulation may increase the risk ... has just posted an article on the new study. ... French scientists studied the work histories of 988 men ... group of workers had been exposed to asbestos only while ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... for the Guinness International Champions Cup Match between Manchester ... Bronx, New York, one of the most iconic locations is ... original Yankee Stadium, but it is quickly becoming a location ... The facility is home to the New York Yankees from ...
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 2Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2
... , NASHVILLE, Tenn. and GLEN ROCK, N.J., ... 76 percent of surveyed pharmacy directors say that by ... only one preferred biologic for all immune conditions, such ... According to the new Formulary Forum report entitled ...
... , , , ... GHDX ) today announced that Kim Popovits, Genomic Health,s Chief ... Growth Conference in Boston, on Thursday, August 13 at 1:30 p.m. ... subsequently archived webcast of the presentation, visit the Investor Relations section ...
... , , HOUSTON, Aug. 6 ... a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated ... trial is being conducted under a Bellicum Investigational New Drug application ... results of the study in 2010. , , ...
... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
... , , NEW YORK, ... synthetic peptide technology shown to significantly help improve the appearance of ... now available through select physicians to help their patients achieve picture ... can be found in leading physician offices for $120 per 1 ...
... , SALT LAKE CITY, Aug. 6 ... silicon nitride ceramic technologies, announced today that Ben Shappley has joined ... Shappley will also serve on the company,s Board of Directors. , ... of orthopaedic and neurosurgical implant experience in both management and senior ...
Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:Ben Shappley Joins Amedica's Leadership Team 2
... a differential medium designed for the ... Selective agents are incorporated for the ... of S. epidermidis and yeast. S. ... in mauve colonies, thus permitting differentiation ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... a 180 watt Xenon short arc lamp. Designed to ... the lamp to the light guide, this light source ... higher watt bulbs. A new IR filtering system and ... amount of heat generated from the light source and ...
... standardize your video equipment has led Linvatec ... couplers to accommodate all of your multi-specialty ... "V mount couplers in both traditional eyecup ... also offer a 20-42mm Zoom "C mount ...
Medicine Products: